Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Genetic medicines could treat certain diseases, however, the current delivery systems available—viral vectors and lipid nanoparticles (LNPs)—pose unique challenges for gene therapy applications. For ...